Are any of the weight‑loss agents phentermine‑topiramate extended‑release, orlistat, or naltrexone‑bupropion extended‑release contraindicated in a patient taking sertraline and quetiapine?

Drug Interactions Between Weight-Loss Medications and Sertraline/Quetiapine

Naltrexone-bupropion is contraindicated or requires significant caution when combined with sertraline due to increased risk of serotonin syndrome and seizures, while phentermine-topiramate and orlistat have no absolute contraindications with this psychiatric medication regimen.

Naltrexone-Bupropion: Significant Interaction Risk

The combination of naltrexone-bupropion with sertraline creates a clinically significant drug interaction that warrants extreme caution or avoidance. 1

Mechanism of Concern

• Bupropion is a potent CYP2D6 inhibitor, which can substantially increase sertraline concentrations since sertraline is partially metabolized by this enzyme 1
• This interaction increases the risk of serotonin syndrome when combining two serotonergic agents (bupropion and sertraline) 1
• Enhanced seizure risk exists, as both bupropion and quetiapine can lower the seizure threshold 1

FDA Labeling Warnings

The naltrexone-bupropion FDA label specifically warns about:

• Increased concentrations of antidepressants (including SSRIs like sertraline) when co-administered with bupropion due to CYP2D6 inhibition 1
• Dose reduction should be considered for the antidepressant when using naltrexone-bupropion 1
• Seizure risk is dose-dependent and increases with concomitant medications that lower seizure threshold 1

Clinical Recommendation

If naltrexone-bupropion must be used with sertraline, sertraline dose reduction is mandatory and close monitoring for serotonin syndrome symptoms (agitation, confusion, tremor, tachycardia) is essential 1. However, alternative weight-loss agents should be strongly preferred in this clinical scenario.

Phentermine-Topiramate: No Absolute Contraindication

Phentermine-topiramate can be used with sertraline and quetiapine without absolute contraindication, though monitoring is required 2

Key Considerations

• No direct pharmacokinetic interaction exists between phentermine-topiramate and sertraline or quetiapine 2
• The FDA label does not list SSRIs or atypical antipsychotics as contraindications 2
• MAOIs are contraindicated (must be discontinued 14 days before starting), but sertraline is an SSRI, not an MAOI 2

Monitoring Requirements

• Blood pressure and heart rate monitoring is essential, as phentermine has sympathomimetic effects and quetiapine can cause orthostatic hypotension 2
• Monitor for mood changes, as topiramate carries a black box warning for suicidal ideation, which could be relevant in patients already on psychiatric medications 2
• Seizure threshold: While topiramate is actually an antiepileptic, quetiapine can lower seizure threshold at higher doses 2

Orlistat: Safest Option

Orlistat has no pharmacokinetic interactions with sertraline or quetiapine and represents the safest choice from a drug interaction perspective 3

Rationale

• Orlistat acts locally in the GI tract by inhibiting pancreatic lipase and has minimal systemic absorption 3
• No CYP450 interactions exist with psychiatric medications 3
• The primary concern is malabsorption of fat-soluble vitamins, not drug interactions 3

Practical Limitations

• Despite safety, the AGA conditionally recommends against orlistat due to modest weight loss (2.8-4.8%) and frequent GI adverse effects 3
• However, when other agents are contraindicated (as with naltrexone-bupropion in this case), orlistat becomes a reasonable option 3

Clinical Algorithm for This Patient

1. First-line choice: Phentermine-topiramate - Most effective among the three options (10.9% weight loss at higher dose) with no absolute contraindication 3

   • Requires BP/HR monitoring and mood assessment 2

2. Second-line choice: Orlistat - Safest interaction profile but least effective 3

   • Consider if cardiovascular concerns exist with phentermine 3

3. Avoid: Naltrexone-bupropion - Significant CYP2D6 interaction with sertraline and seizure risk concerns 1

   • If absolutely necessary, requires sertraline dose reduction and intensive monitoring 1

Additional Considerations

Weight effects of current medications: Sertraline causes minimal weight change (1-2 pounds in trials), while quetiapine is associated with significant weight gain 4. The need for weight-loss medication may be partially driven by quetiapine itself, which should be discussed with the prescribing psychiatrist 4.

Newer alternatives not listed: GLP-1 receptor agonists (semaglutide 2.4 mg, tirzepatide) have no significant interactions with sertraline or quetiapine and achieve superior weight loss (11-20%) compared to all three options mentioned 3.